Симуляция графика K-линий, фактические данные указаны на торговой странице
Ключевые данные
Открытие вчера
$1.45
Пред. закрытие
$1.42
Вчерашний диапазон
$1.38 - $1.48
Диапазон 52 нед.
$1.03 - $5.55
Объем торговли
626.325K
МС
$168.647M
P/E
--
EPS
$-1.27
Обзор компании
NASDAQ
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts.
СекторHEALTHCARE
ОтрасльBIOTECHNOLOGY
Штаб-квартира321 HARRISON AVENUE, BOSTON, MA, UNITED STATES, 02118
Pyxis Oncology focuses on developing innovative cancer therapies aimed at addressing unmet needs in oncology. The company is engaged in the research and development of antibody-drug conjugates (ADCs) and immunotherapies designed to target specific cancer pathways. Its portfolio includes proprietary assets and collaborations to deliver targeted treatments for patients.
Pyxis Oncology (PYXS) operates in the Healthcare sector within the Biotechnology and Pharmaceuticals industry. This sector specializes in developing advanced medical solutions, including drug therapies and innovative treatments for diseases such as cancer.
Pyxis Oncology primarily generates revenue through partnerships, licensing agreements, and potential commercialization of its oncology drug candidates. As a clinical-stage biotechnology company, its current focus is on advancing its pipeline through development stages, which could lead to monetization in the form of milestone payments and, eventually, drug sales.
Pyxis Oncology faces competition from other biotechnology companies developing innovative cancer therapies, such as ADC Therapeutics, Seagen, and ImmunoGen. These companies are also focused on antibody-drug conjugates and targeted cancer treatments, creating a competitive environment in research and development.
Key risks for Pyxis Oncology (PYXS) include the uncertainty surrounding regulatory approvals, clinical trial outcomes, and competition in the biotech space. Additionally, as a clinical-stage company, it relies on external funding to support its operations. Market sentiment and broader economic factors may also impact the stock's performance.
No, Pyxis Oncology does not pay dividends as it is a clinical-stage biotech company. Biotech firms in the R&D phase typically reinvest any resources into developing their pipeline and advancing their products, rather than distributing dividends to shareholders.
Pyxis Oncology has opportunities for growth through its innovative pipeline of cancer therapies. If its drug candidates successfully complete clinical trials and receive regulatory approvals, it could position itself as a key player in oncology. Partnerships and licensing agreements also provide additional avenues for expanding its market position.
Pyxis Oncology’s valuation reflects its clinical-stage status, where market capitalization is influenced by investor expectations surrounding pipeline progress, regulatory milestones, and potential future revenue. It is subject to fluctuations based on updates related to trials, partnerships, and overall market sentiment within the biotech industry.
Предупреждение о рисках
1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.